Shingrix Effective Against Shingles for up to 11 Years Post-Vaccination: Daily Dose

_{©New Africa/AdobeStock}

Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.

Last week, we reported on findings from a long-term follow-up clinical trial that examined the efficacy, safety, and immunogenicity of Shingrix (Recombinant Zoster Vaccine or RZV, GSK) in adults aged 50 years and older.

The study

The ZOSTER-049 study is an extension from 2 phase 3 randomized clinical trials, ZOE-50 and ZOE-70. ZOSTER-049 evaluated the efficacy, safety, and immunogenicity of RZV in adults aged 50 years and older at time of vaccination, for 6 additional years after the ZOE-50 and ZOE-70 studies were completed, and up to approximately 11 years of follow-up.

Over 7000 adults from 18 countries across 5 continents were included in the ZOSTER-049 trial, with vaccine recipients compared to historical controls.

The findings

The final study data showed 79.7% vaccine efficacy (VE) among participants aged 50 years and older cumulatively between 6 to 11 years after vaccination (95% CI 73.7–84.6). Also, RZV was 82% effective in participants at year 11 (95% CI 63.0–92.2), showing VE remains high in each year following vaccination.

Among participants aged 70 years and older, VE was 73.1% from 6 to 11 years after vaccination (95% CI 62.9-80.9), demonstrating high VE rates across all age groups.

Click here for more details.